Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Small cell lung cancer

Recruiting

Registered drugNo placebo

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Topotecan Hydrochloride

Contact Research Centre

Cardiac failure+1

Recruiting

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Poland

Participants:18–64 years · 65+ years

Contact Research Centre

Small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Squamous cell carcinoma of lung+6

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:BNT327

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Baxdrostat

Contact Research Centre

Myocardial infarction

Recruiting

Registered drug

Study on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Sodium Chloride

Contact Research Centre

Acute myocardial infarction

Recruiting

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Selatogrel

Contact Research Centre

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting

Investigational

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Finerenone

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Azd5004

Contact Research Centre

Bladder cancer

Recruiting

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Non-small cell lung cancer stage III

Recruiting

Registered drugNo placebo

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Find therapies in clinical trials near you

36 trials match your criteria

Small cell lung cancer

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Cardiac failure+1

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Small cell lung cancer+2

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Squamous cell carcinoma of lung+6

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Myocardial infarction

Study on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency

Acute myocardial infarction

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Heart failure with preserved ejection fraction

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Bladder cancer

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Non-small cell lung cancer

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Non-small cell lung cancer stage III

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.